NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight during sleep hours after 12 weeks of treatment. Further analyses will be conducted on the initial data, including submission for publication of comprehensive results at a later date.
Overactive bladder is a treatable medical condition caused by involuntary contractions or spasms of the bladder muscle. Overactive bladder symptoms of urgency, frequency or urge urinary incontinence can be bothersome and can have a significant impact on important aspects of people’s lives. Approximately 33 million Americans are estimated to suffer from overactive bladder symptoms. Despite its prevalence, overactive bladder is often unrecognized and untreated.
“Many patients with overactive bladder experience frequent interruptions during sleep hours from urinary urgency, which can be very disruptive and bothersome. In this study, Toviaz demonstrated efficacy in reducing the number of nocturnal urgency episodes,” said Steven J. Romano, M.D., senior vice president, Head, Medicines Development Group, Global Primary Care Business Unit, Pfizer Inc.
Study A0221048 was a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to compare the efficacy and safety of a flexible dose regimen of fesoterodine to placebo in subjects with symptoms of overactive bladder, including nocturnal urinary urgency. The 12-week trial evaluated a total of 937 individuals at 108 sites in the U.S. After an initial 2-week period during which subjects received placebo treatment, subjects were randomized either to a fesoterodine 4 mg arm (463 subjects) or to placebo (474 subjects) if they had less than or equal to a 35% reduction in nocturnal urgency episodes. After 4 weeks of treatment, based on patient self-reporting, investigators could increase the daily dose of fesoterodine to 8 mg per day. The primary endpoint was change in mean number of nocturnal urinary urgency episodes per day at Week 12 relative to baseline. No significant safety concerns were identified, and the most common adverse events were dry mouth and constipation.
Toviaz® (fesoterodine fumarate) treats the symptoms of overactive bladder (leaks, strong sudden urges to go, going too often).
Important Safety Information
If you have certain stomach problems, glaucoma, or cannot empty your bladder, you should not take Toviaz.
Toviaz may cause allergic reactions that may be serious. If you experience swelling of the face, lips, throat, or tongue, stop taking Toviaz and get emergency medical help right away.
Medicines like Toviaz can cause blurred vision, drowsiness, and decreased sweating. Use caution when driving, doing unsafe tasks, or in especially hot environments, until you know how Toviaz affects you. Drinking alcohol while taking medicines such as Toviaz may cause increased drowsiness.
The most common side effects are dry mouth and constipation.
Toviaz has benefits and risks. There may be other options. To learn more about Toviaz, please see the Full Prescribing and Patient Information.
Pfizer Inc.: Working Together for a Healthier World®
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.
MacKay Jimeson (media), 212-733-2324
Suzanne Harnett (investors), 212-733-8009
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical